Gabelli Funds LLC Lowers Holdings in Cencora, Inc. $COR

Gabelli Funds LLC trimmed its position in Cencora, Inc. (NYSE:COR) by 41.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,970 shares of the company’s stock after selling 18,440 shares during the period. Gabelli Funds LLC’s holdings in Cencora were worth $8,158,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. United Bank raised its position in shares of Cencora by 4.5% in the second quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after buying an additional 305 shares in the last quarter. Nebula Research & Development LLC purchased a new position in Cencora during the second quarter worth about $595,000. Treasurer of the State of North Carolina increased its stake in Cencora by 7.9% in the 2nd quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock worth $25,647,000 after acquiring an additional 6,244 shares during the last quarter. Diversify Advisory Services LLC increased its stake in Cencora by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock worth $747,000 after acquiring an additional 1,253 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in shares of Cencora by 26.0% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock valued at $22,025,000 after acquiring an additional 15,154 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Trading Up 0.5%

Shares of COR stock opened at $311.42 on Tuesday. The business has a 50-day moving average price of $285.51 and a two-hundred day moving average price of $316.05. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The firm has a market cap of $60.59 billion, a P/E ratio of 23.88, a price-to-earnings-growth ratio of 1.72 and a beta of 0.58.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the company posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora announced that its Board of Directors has initiated a share buyback plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Insider Buying and Selling

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $270.23 per share, with a total value of $148,626.50. Following the completion of the purchase, the director owned 4,359 shares of the company’s stock, valued at $1,177,932.57. The trade was a 14.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.38% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Barclays dropped their price target on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Bank of America raised their target price on shares of Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research note on Wednesday, June 24th. Weiss Ratings lowered shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th. Citigroup cut their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Morgan Stanley set a $342.00 price target on shares of Cencora in a report on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus price target of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.